Profil Financier
Andreas Struengmann & family occupe actuellement le rang #311 du classement mondial StarFortune (secteur santé & biotech). Fortune nette estimée : $11.3 B (+$260 sur 24h).
Andreas Struengmann and twin brother Thomas were early backers of BioNTech, which partnered with Pfizer to make a vaccine for Covid-19.
The brothers cofounded generic drugmaker Hexal in 1986 and sold it to Novartis in 2005 for some $7 billion.
The brothers invest in biotech, pharma, life sciences and healthcare companies through their Zug, Switzerland-based investment firm, Santo Holding.
In 2008, they established a neuroscience research center in Frankfurt named after their father, Ernst Struengmann.
After studying medicine in Freiburg, Germany, Andreas worked as a doctor in South Africa.